Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
26
CELZ Quote, Financials, Valuation and Earnings
Last price:
$1.86
Seasonality move
:
347.62%
Day range:
$2.09 - $2.21
52-week range:
$1.69 - $6.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
769.40x
P/B ratio:
0.97x
Volume:
55.5K
Avg. volume:
90.4K
1-year change:
-9.48%
Market cap:
$5.4M
Revenue:
$11K
EPS (TTM):
-$2.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CELZ
Creative Medical Technology Holdings, Inc.
|
-- | -$0.48 | -100% | -67.05% | $20.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CELZ
Creative Medical Technology Holdings, Inc.
|
$2.10 | $20.00 | $5.4M | -- | $0.00 | 0% | 769.40x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.86 | $2.00 | $706.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CELZ
Creative Medical Technology Holdings, Inc.
|
-- | 4.049 | -- | 20.56x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CELZ
Creative Medical Technology Holdings, Inc.
|
-$31.1K | -$1.3M | -89.3% | -89.3% | -55349.27% | -$1.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Creative Medical Technology Holdings, Inc. vs. Competitors
-
Which has Higher Returns CELZ or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -54603.23% compared to Creative Medical Technology Holdings, Inc.'s net margin of -255.85%. Creative Medical Technology Holdings, Inc.'s return on equity of -89.3% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CELZCreative Medical Technology Holdings, Inc.60% -$0.48 $5.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CELZ or NBY?
Creative Medical Technology Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 852.38%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Creative Medical Technology Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Creative Medical Technology Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CELZCreative Medical Technology Holdings, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CELZ or NBY More Risky?
Creative Medical Technology Holdings, Inc. has a beta of 5.323, which suggesting that the stock is 432.282% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CELZ or NBY?
Creative Medical Technology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Creative Medical Technology Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CELZ or NBY?
Creative Medical Technology Holdings, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Creative Medical Technology Holdings, Inc.'s net income of -$1.2M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Creative Medical Technology Holdings, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Creative Medical Technology Holdings, Inc. is 769.40x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CELZCreative Medical Technology Holdings, Inc.769.40x -- -- -$1.2M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns CELZ or NNVC?
NanoViricides, Inc. has a net margin of -54603.23% compared to Creative Medical Technology Holdings, Inc.'s net margin of --. Creative Medical Technology Holdings, Inc.'s return on equity of -89.3% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital CELZCreative Medical Technology Holdings, Inc.60% -$0.48 $5.6M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About CELZ or NNVC?
Creative Medical Technology Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 852.38%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that Creative Medical Technology Holdings, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Creative Medical Technology Holdings, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CELZCreative Medical Technology Holdings, Inc.1 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is CELZ or NNVC More Risky?
Creative Medical Technology Holdings, Inc. has a beta of 5.323, which suggesting that the stock is 432.282% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock CELZ or NNVC?
Creative Medical Technology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Creative Medical Technology Holdings, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CELZ or NNVC?
Creative Medical Technology Holdings, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Creative Medical Technology Holdings, Inc.'s net income of -$1.2M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Creative Medical Technology Holdings, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Creative Medical Technology Holdings, Inc. is 769.40x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CELZCreative Medical Technology Holdings, Inc.769.40x -- -- -$1.2M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns CELZ or OGEN?
Oragenics, Inc. has a net margin of -54603.23% compared to Creative Medical Technology Holdings, Inc.'s net margin of --. Creative Medical Technology Holdings, Inc.'s return on equity of -89.3% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital CELZCreative Medical Technology Holdings, Inc.60% -$0.48 $5.6M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About CELZ or OGEN?
Creative Medical Technology Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 852.38%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 132.83%. Given that Creative Medical Technology Holdings, Inc. has higher upside potential than Oragenics, Inc., analysts believe Creative Medical Technology Holdings, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CELZCreative Medical Technology Holdings, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is CELZ or OGEN More Risky?
Creative Medical Technology Holdings, Inc. has a beta of 5.323, which suggesting that the stock is 432.282% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock CELZ or OGEN?
Creative Medical Technology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Creative Medical Technology Holdings, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CELZ or OGEN?
Creative Medical Technology Holdings, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Creative Medical Technology Holdings, Inc.'s net income of -$1.2M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Creative Medical Technology Holdings, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Creative Medical Technology Holdings, Inc. is 769.40x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CELZCreative Medical Technology Holdings, Inc.769.40x -- -- -$1.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns CELZ or PTN?
Palatin Technologies has a net margin of -54603.23% compared to Creative Medical Technology Holdings, Inc.'s net margin of --. Creative Medical Technology Holdings, Inc.'s return on equity of -89.3% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CELZCreative Medical Technology Holdings, Inc.60% -$0.48 $5.6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CELZ or PTN?
Creative Medical Technology Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 852.38%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Creative Medical Technology Holdings, Inc., analysts believe Palatin Technologies is more attractive than Creative Medical Technology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CELZCreative Medical Technology Holdings, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is CELZ or PTN More Risky?
Creative Medical Technology Holdings, Inc. has a beta of 5.323, which suggesting that the stock is 432.282% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CELZ or PTN?
Creative Medical Technology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Creative Medical Technology Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CELZ or PTN?
Creative Medical Technology Holdings, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Creative Medical Technology Holdings, Inc.'s net income of -$1.2M is higher than Palatin Technologies's net income of --. Notably, Creative Medical Technology Holdings, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Creative Medical Technology Holdings, Inc. is 769.40x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CELZCreative Medical Technology Holdings, Inc.769.40x -- -- -$1.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CELZ or TOVX?
Theriva Biologics, Inc. has a net margin of -54603.23% compared to Creative Medical Technology Holdings, Inc.'s net margin of --. Creative Medical Technology Holdings, Inc.'s return on equity of -89.3% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CELZCreative Medical Technology Holdings, Inc.60% -$0.48 $5.6M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CELZ or TOVX?
Creative Medical Technology Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 852.38%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Creative Medical Technology Holdings, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Creative Medical Technology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CELZCreative Medical Technology Holdings, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CELZ or TOVX More Risky?
Creative Medical Technology Holdings, Inc. has a beta of 5.323, which suggesting that the stock is 432.282% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock CELZ or TOVX?
Creative Medical Technology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Creative Medical Technology Holdings, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CELZ or TOVX?
Creative Medical Technology Holdings, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Creative Medical Technology Holdings, Inc.'s net income of -$1.2M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Creative Medical Technology Holdings, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Creative Medical Technology Holdings, Inc. is 769.40x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CELZCreative Medical Technology Holdings, Inc.769.40x -- -- -$1.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
